Want to see AU:SOM full AI Analyst Report?
SOM Stock Chart & Stats
AU$0.56
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.56
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.42 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$98.90M
Enterprise ValueAU$159.83
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)―
Beta1.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,768,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside33.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth (latest +11.22%) indicates increasing adoption of SomnoMed’s oral appliance therapy across its channels. Over a multi-month horizon, steady revenue expansion supports scale, improves pricing leverage and underpins investments in distribution and product support.
High Gross MarginsA gross margin near 60% signals durable product-level economics and pricing power for custom oral appliances. Strong margins provide flexibility to fund R&D, sales and international expansion while helping absorb operating costs as the company scales its clinical and distributor networks.
Improving Cash Generation & Low LeverageA >562% increase in free cash flow and positive operating cash flow despite net losses show meaningful cash conversion. Combined with conservative leverage (D/E ~0.17), this enhances financial resilience, funds operations and growth initiatives and reduces near-term refinancing risk.
Bears Say
Persistent Profitability ShortfallOngoing negative net profit and EBIT margins indicate the business has not reached sustained profitability. Over the coming months this constrains retained earnings, limits capacity to fund longer-term initiatives from profits and may require continued external capital to support growth.
Negative Return On EquityA negative ROE shows the firm is not generating returns on shareholder capital even with low leverage. Structurally, this raises concerns about capital allocation effectiveness and the company’s ability to deliver investor returns absent a meaningful improvement in operating profitability.
Dependence On Clinical Workflow And ReimbursementSales rely on clinician diagnosis, dentist fitting workflows and reimbursement regimes. These structural dependencies create uneven adoption across markets and long sales cycles; reimbursement or referral headwinds can materially slow durable revenue growth and replacement-device demand.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.42 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$98.90M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,768,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.75 (33.93% Upside)
AU$0.75 (33.93% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(33.93% Upside)